Atai Beckley N.V. Business Summary

Atai Beckley N.V. (ATAI) is a clinical-stage biopharmaceutical company utilizing a decentralized platform model to develop psychedelic-inspired and non-hallucinogenic neuroplastogens for neuropsychiatric disorders. The company generates revenue through strategic licensing, milestone-based R&D collaborations, and intellectual property partnerships, though it currently operates as a pre-commercial entity with primary value driven by its clinical pipeline. Its core business segments focus on rapid-acting treatments for treatment-resistant depression (TRD) and social anxiety disorder, led by its Phase 3-ready BPL-003 (intranasal 5-MeO-DMT) and Phase 2 candidates VLS-01 (buccal DMT) and EMP-01 (oral R-MDMA). Atai Beckley competes with Compass Pathways, MindMed, GH Research, and Cybin, distinguishing itself through a consolidated IP portfolio and a cash runway extending into 2029 following its late 2025 merger with Beckley Psytech. The company was co-founded by Christian Angermayer and Dr. Srinivas Rao, the latter of whom serves as the current Chief Executive Officer. The executive leadership team includes Chief Financial Officer Anne Johnson, Chief Operating Officer Gerd Kochendoerfer, Chief Scientific Officer Glenn Short, and Chief Medical Officer Kevin Craig, many of whom hold deep expertise from legacy roles at Otsuka Pharmaceutical and Regeneron. Notable institutional backing includes Peter Thiel’s Thiel Capital, Apeiron Investment Group, and Ferring Ventures. The Board of Directors is led by Chairman Christian Angermayer and Vice Chairman Scott Braunstein, M.D., with Robert Hershberg, M.D., Ph.D., providing clinical oversight following the company’s 2025 redomiciliation to the United States.